Dedicated to transforming the lives of patients with debilitating chronic diseases through local, targeted drug therapy INVESTOR PRESENTATION JUNE 2022 DISCLAIMER This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company's clinical advancement and effic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Address of principal executive offices) (Zip Code) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39273 Lyra Therapeutics, Inc. (Exact name of Registrant as specified in its Chart ...

Dedicated to transforming the lives of patients with debilitating chronic diseases through local, targeted drug therapy INVESTOR PRESENTATION FEBRUARY 2022 DISCLAIMER This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company's clinical advancement and e ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Stephanie Marks - Argot Partners Maria Palasis - President and CEO Jason Cavalier - CFO Robert Kern - Chief Medical Officer Corinne Noyes - SVP-Commercial Strategy & Market Development Conference Call Participants Tim Lugo - William Blair Bert Hazlett - BTIG Chris Howerton - Jefferies Ashwani Verma - Bank of America Operator Good day, and thank you for standing by. Welcome to the Lyra Ther ...

For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Stephanie Marks - Investor Relations, Argot Partners Maria Palasis - President & Chief Executive Officer Robert Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior Vice President, Commercial Strategy & Market Development Conference Call Participants Bert Hazlett - BTIG Tim Lugo - William Blair Ashwani Verma - Bank of America Operator Welcome to the Lyra Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Stat ...

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Company Participants Stephen Jasper - Principal, Gilmartin Group Maria Palasis - President and Chief Executive Officer Rob Kern - Chief Medical Officer Don Elsey - Chief Financial Officer Conference Call Participants Perry Mayo-Malasky - BTIG Jason Gerberry - Bank of America Chris Howerton - Jefferies Operator Welcome to the Lyra Therapeutics First Quarter 2021 Financial Results and Corporate Update Conference Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39273 Lyra Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Sta ...